에 대한 최신 뉴스 Centene (NYSE:CNC) 주식

Centene

Centene is a managed care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of September, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare Advantage (about 5%). The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program and has a military contract.

Large Cap

News

Short Sellers

Movers

Trading Ideas

ASML

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

ERIE

KLAC

LRCX

Citigourp Global Markets 2% Protected Notes Linked To The Djia

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 니오(NYSE:NIO)의 주식이 지난주 16.35% 하락했다. 이는 미국에 상장된 중국 주식들이 중국의 9월 수출이 예상치를 밑돌면서 하락한 후 발생한 일이다. 중국 경기 부양책에 대한 불확실성도 최근 주식에 악영향을 미쳤다.

니오, ASML 및 CVS 헬스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 14일-18일)

Centene Corp

Canna Corp

CHINA NUCLEAR ENERGY TECH by CHINA NUCLEAR ENERGY TECHNOLOGY CORP LTD.

Coincheck Group NV

CANCER CAPITAL CORP by Cancer Capital Corp.

Cancer Capital Corp

CONNECTED MEDIA TECHS INC by Connected Media Technologies, Inc.

Connected Media Technologies Inc

CHUN CAN CAPITAL GROUP by Chun Can Capital Group

Chun Can Capital Group

Core Nickel Corp

CONDUIT CAPITAL LTD ORD by Conduit Capital Ltd.

Range Cancer Therapeutics ETF

CHINA CASTSON 81 FINCE by CHINA CASTSON 81 FINANCE CO.

CHINA TELETECH HLDGS INC by China Teletech Holding, Inc.

China Teletech Holding Inc

Centene's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has risen 7.58% since its last report. The company recently reported that it has 16.31 million shares sold short, which is 3.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Centene Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734703224_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Centene has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 5.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Ideas

(CNC) - Analyzing Centene's Short Interest

According to a report, U.S. healthcare spending grew by 7.5% to $4.9 trillion in 2023. The increase was fueled by higher enrollment in private health plans and expanded use of medical services, driven by legislative changes and post-pandemic rebounds in care utilization.
Healthcare spending accounted for 17.6% of the U.S. economy, outpacing GDP growth of 2.9%. Spending on retail prescription drugs <a target="_blank" href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2024.01375" rel="noreferrer noopener">saw</a> the most significant rise, jumping 11.4% to $449.7 billion.
The report attributed this to increased use of medications for obesity and diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The rapid growth in spending for drugs used to treat diabetes and obesity contributed to faster overall growth in retail prescription drug expenditures and private health insurance and Medicare spending growth.
Hospital care spending rose 10.4% to $1.5 trillion in 2023, marking the fastest growth since 1990. Hospital discharges increased by 1.6%, with Medicare beneficiaries driving higher outpatient service utilization.
Spending on physician and clinical services also climbed by 7.4% to $978 billion, with private insurance and Medicare patients contributing to this rise.
Enrollment in private health insurance grew by 1.6%, adding 3.3 million Americans.
Private insurance spending surged by 11.5%, reaching $1.5 trillion and accounting for 30% of national healthcare expenditures.
Medicare spending grew 8.1% to $1 trillion, representing 21% of total healthcare spending. Medicaid spending, however, grew more slowly at 7.9%, reflecting the end of the COVID-19 public health emergency.
The report also revealed that 92.5% of Americans had health insurance in 2023, up from 92.0% in 2022, underscoring the broader coverage expansion in recent years.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42599673/amazon-has-20000-rivian-electric-delivery-vans-in-fleet-heres-what-could-be-next-for-both-companies">Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here&#8217;s What Could Be Next For Both Companies</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Biotech

Government

Health Care

General

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 15 years by 5.53% on an annualized basis producing an average annual return of 17.18%. Currently, Centene has a market capitalization of $30.04 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 15 years ago, it would be worth $10,701.64 today based on a price of $59.50 for CNC at the time of writing.
<h3>Centene's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734625810_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Centene Stock In The Last 15 Years

JP Morgan analyst John Stansel assumes Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight rating and lowers Price Target of $75.

Price Target

Initiation

Analyst Ratings

JP Morgan Assumes Centene at Overweight, Lowers Price Target of $75

WIIM

Centene shares are trading higher after the UBS upgraded the stock from Neutral to Buy and raised its price target from $79 to $80. Also, Barclays maintained an Overweight rating on the stock and raised its price target from $91 to $93.

Stephens &amp; Co. analyst Scott Fidel maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Equal-Weight and lowers the price target from $75 to $73.

Stephens & Co. Maintains Equal-Weight on Centene, Lowers Price Target to $73

Truist Securities analyst Ryan MacDonald maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Buy and lowers the price target from $89 to $84.

Truist Securities Maintains Buy on Centene, Lowers Price Target to $84

Barclays analyst Andrew Mok maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and raises the price target from $91 to $93.

Barclays Maintains Overweight on Centene, Raises Price Target to $93

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wolfe Research analyst Darrin Peller upgraded the rating for PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) from Peer Perform to Outperform and announced a $107 price target. PayPal shares closed at $89.40 on Thursday. See how other analysts view this stock.</li>
<li>B of A Securities analyst Tal Liani upgraded Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) from Neutral to Buy and raised the price target from $70 to $95. Ciena shares closed at $84.52 on Thursday. <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Kyle Peterson upgraded Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) from Hold to Buy and announced a $100 price target. Upstart shares closed at $77.08 on Thursday. See how other analysts view this stock.</li>
<li>UBS analyst A.J. Rice upgraded the rating for Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Neutral to Buy and increased the price target from $79 to $80. Centene shares closed at $58.00 on Thursday. <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Stephen Baxter upgraded the rating for Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Underweight to Equal-Weight and raised the price target from $101 to $127. Cardinal Health shares closed at $117.46 on Thursday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PYPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="622" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-1024x622.png" alt="" class="wp-image-691544" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-1024x622.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-768x466.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>

Upgrades

Markets

CIEN

PYPL

UPST

This PayPal Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Oppenheimer analyst Michael Wiederhorn maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Outperform and lowers the price target from $95 to $85.

Oppenheimer Maintains Outperform on Centene, Lowers Price Target to $85

UBS analyst A.J. Rice upgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Neutral to Buy and raises the price target from $79 to $80.

UBS Upgrades Centene to Buy, Raises Price Target to $80

I admit it: I am something of a geek.
I spend a lot of time sitting around reading articles, crunching numbers, and engaging in other research-focused activities.
One of my favorite ways to spend an afternoon is with a game in the background (preferably baseball, but there has to be an offseason), reading the latest academic studies and insights.
Recently, I spent some time with a study on insider buying titled &#8220;Are CFOs&#8217; Trades More Informative Than CEOs&#8217; Trades?&#8221;
As it turns out, they are.
Everyone focuses on the CEO. After all, he is the top executive who sees everything: all the plans, all the ideas, all the sales figures, everything.
The CEO is the ship&#8217;s captain who sees all and theoretically knows all.
Why, then, does the CFO outperform?
Keeping our ship analogy, the CEO may be the captain, but the CFO oversees the engine room and the power plant.
He knows what cash is coming in, where it is going, and how the excess is being spent.
The CFO knows how much they owe and to whom they owe it.
The CFO is also present in every meeting and sees every plan and vision laid out by the CEO and other executives.
He also knows how these plans will impact the business&#8217;s financial health.
She is also best positioned to judge how these plans will likely impact the company&#8217;s value.
When the Chief Financial Officer buys, it is because the business is trading for less than the ultimate insider view says it is worth.
Here are three companies with recent significant buying by the Chief Financial Officer:
Dorchester Minerals, L.P. (Ticker: DMLP) is a master limited partnership that acquires, owns, and manages producing and non-producing mineral, royalty, overriding royalty, net profits, and leasehold interests across the United States.
Its diversified portfolio spans 593 counties and parishes in 28 states, providing exposure to various oil and gas assets.
While the company is currently most active in the Permian and Bakken regions, it also has significant acreage in the Utica Shale and Marcellus Shale regions, which hold enormous amounts of natural gas.
Most energy industry insiders think that natural gas will be in huge demand as the energy source for developing AI to its full potential.
As a royalty trust, Dorchester is paid for every drop of oil and gas produced on the acreage they own. At the current price, the yield on the shares is over 10%.
CFO Leslie Moriyama is clearly a big believer in higher energy prices, as she has recently purchased over $500,000 worth of additional stock in the company.
HA Sustainable Infrastructure Capital, Inc. (Ticker: HASI), formerly known as Hannon Armstrong Sustainable Infrastructure Capital, Inc., is a leading investor in climate solutions, focusing on energy efficiency, renewable energy, and other sustainable infrastructure markets across the United States.
HA Sustainable Infrastructure Capital, Inc. (HASI) maintains a diversified portfolio across three primary markets: Behind-the-Meter (BTM), Grid-Connected (GC), and Fuels, Transport &amp; Nature (FTN). As of June 30, 2024, the portfolio distribution was approximately 47% in BTM, 40% in GC, and 13% in FTN.
The company&#8217;s investments encompass various asset classes, including equity, joint ventures, land ownership, lending, and other financing transactions. Notable investments include a structured equity investment in a 2.0 GW portfolio of contracted wind, solar, and solar-plus-storage projects, and a senior debt investment in a portfolio of operating landfill gas-to-renewable natural gas and wastewater treatment biogas-to-renewable natural gas plants.
CFO Marc Pangburn is not buying the death of renewables story, as he recently purchased a six-figure stake in the company.
Centene Corporation (Ticker: CNC), headquartered in St. Louis, Missouri, is a leading managed care company specializing in government-sponsored healthcare programs. Founded in 1984, Centene has become a significant intermediary for government-sponsored and privately insured healthcare plans, offering a comprehensive range of services to individuals and families across the United States. The company&#8217;s portfolio includes Medicaid, Medicare Advantage, and Marketplace insurance plans, serving over 28 million members nationwide.
In the third quarter of 2024, Centene reported total revenues of $42.0 billion, marking a 10% increase from the same period in the previous year. This growth was primarily driven by a 22% increase in Marketplace membership and a 49% rise in Medicare Prescription Drug Plans. The company&#8217;s adjusted diluted earnings per share stood at $1.62, surpassing analysts&#8217; expectations.
Despite a decline in Medicaid membership due to redeterminations, Centene&#8217;s diversified portfolio allowed it to navigate these challenges effectively. The company reaffirmed its full-year adjusted diluted EPS guidance of greater than $6.80, reflecting confidence in its financial outlook.
The stock has sold off this year, finally attracting the interest of CFO Andrew Asher, who recently purchased $1 million worth of the company.

Opinion

DMLP

Hannon Armstrong Sustainable Infrastructure Capital

HASI

C-Suite Buy of the Week: Executives' Investments Offer Clues to Market Directions

On Thursday, Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) outlined its 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42456151/centene-corporation-announces-2025-guidance" rel="noreferrer noopener">financial guidance</a>.
For fiscal year 2025, the health insurance plan provider expects total revenues of&nbsp;$166.5 billion&nbsp;to&nbsp;$169.5 billion, compared to a consensus of $166.58 billion.
The guidance includes premium and service revenues of&nbsp;$154.0 billion&nbsp;to&nbsp;$156.0 billion. The company expects GAAP EPS of greater than&nbsp;$6.19, with adjusted EPS of greater than&nbsp;$7.25 compared to the consensus of $6.97.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The company expects a Health benefits ratio (HBR) of 88.4% to 89.0%.
The insurer forecasts a 2025 selling, general, and administrative (SG&amp;A) expense ratio of 8.1% to 8.7%, with an adjusted SG&amp;A expense ratio of 8.1% to 8.7%.
The company reaffirms its 2024 premium and service revenues guidance if&nbsp;$143.5 billion&nbsp;to&nbsp;$144.5&nbsp;billion, HBR guidance if 88.3% to 88.5%, and adjusted diluted EPS guidance <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41542651/centene-says-it-is-positioned-to-capture-long-term-growth-in-government-sponsored-healthcare-lifts-" rel="noreferrer noopener">of greater than&nbsp;$6.80</a>.
&#8220;Centene is a mission driven organization, dedicated to delivering high quality outcomes for more than 28 million members, many of whom are among the nation&#8217;s most medically complex and historically underserved populations. Over the last three years we improved our core operations and invested in the experience of our customers and providers, all while delivering on our financial commitments,&#8221; said Chief Executive Officer of Centene,&nbsp;Sarah London.
Full-year 2024 earnings will be reported on February&nbsp;4, 2025.
Price Action: CNC stock is up 1.92% at $57.99 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42462096/keros-therapeutics-pauses-two-treatment-arms-in-mid-stage-hypertension-trial-stock-plummets" target="_blank" rel="noreferrer noopener">Keros Therapeutics Loses 75% Value In A Single Session &#8211; Here&#8217;s Why</a></li>
</ul>

Earnings

Guidance

Why Is Insurance Firm Centene Stock Trading Higher On Thursday?

Centene Exec Says Co Would "Love To Responsibly Acquire" Some Health Plans That Adds To Its Core Businesses

The Company reaffirms its 2024 premium and service revenues guidance in the previously announced range of $143.5 billion to $144.5&nbsp;billion, HBR guidance in the previously announced range of 88.3% to 88.5% and adjusted diluted EPS guidance of greater than $6.80.

Centene Expects 2025 Total revenues Of $166.5B-$169.5B Compared To Consensus Of $166.577B

For its 2025 fiscal year, the Company's guidance is as follows:
<ul>
<li>Total revenues of $166.5 billion to $169.5 billion.</li>
<li>Premium and service revenues of $154.0 billion to $156.0 billion.</li>
<li>GAAP diluted earnings per share (EPS) of greater than $6.19.</li>
<li>Adjusted diluted EPS of greater than $7.25.</li>
<li>Health benefits ratio (HBR) of 88.4% to 89.0%.</li>
<li>Selling, general and administrative (SG&amp;A) expense ratio of 8.1% to 8.7%.</li>
<li>Adjusted SG&amp;A expense ratio of 8.1% to 8.7%.</li>
<li>Effective tax rate of 21.5% to 22.5%.</li>
<li>Adjusted effective tax rate of 22.0% to 23.0%.</li>
<li>Diluted shares outstanding of 491.0 million to 494.0 million.</li>
</ul>

Centene Expects 2025 Adjusted EPS Of Greater Than $7.25 Compared To Consensus Of $6.97, Reaffirms 2024 Adjusted EPS Guidance Of Greater Than $6.80 Vs. Consensus Of $6.70

Cantor Fitzgerald analyst Sarah James reiterates Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and maintains $90 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Centene, Maintains $90 Price Target

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 2.42% on an annualized basis producing an average annual return of 10.86%. Currently, Centene has a market capitalization of $28.75 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 20 years ago, it would be worth $7,765.47 today based on a price of $56.95 for CNC at the time of writing.
<h3>Centene's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733860819_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Centene 20 Years Ago Would Be Worth This Much Today

Across the recent three months, 8 analysts have shared their insights on Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $82.25, along with a high estimate of $91.00 and a low estimate of $52.00. Highlighting a 7.06% decrease, the current average has fallen from the previous average price target of $88.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733839313_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Centene among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$52.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Lance Wilkes</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$93.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Centene. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Centene compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Centene's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Centene's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CNC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Centene analyst ratings.</a>
<h2>Discovering Centene: A Closer Look</h2>
Centene is a managed care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of September, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare Advantage (about 5%). The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program and has a military contract.
<h3>Centene's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 10.46%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Centene's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.7%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Centene's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.61% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Centene's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.86%, the company showcases efficient use of assets and strong financial health.
Debt Management: Centene's debt-to-equity ratio is below the industry average. With a ratio of 0.64, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Centene Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)

Centene shares are trading lower after Jefferies downgraded the stock from Hold to Underperform and lowered its price target from $68 to $52.

Worst performing stocks for tax loss selling – Wolfe

JPMorgan upgraded Centene (CNC) to Overweight from Neutral with a price target of $75, down from $80, after assuming coverage of the name. Entering...

Centene assumed with Overweight from Neutral at JPMorgan

IHF: Healthcare Dashboard For December

Elevance downgraded at Morgan Stanley on Medicaid headwinds

Hartford MidCap Value Fund Q3 2024 Commentary

U.S. healthcare spending climbs 7.5% in 2023

In a regulatory filing, Centene (CNC) disclosed that its director Thomas Greco bought 17K shares of common stock on December 18 in a total transact...

Centene director buys $1.02M in common stock

Thursday's total option volume of 66.9 million contracts resulted in net open interest growth of 5.13 million calls and 2.53 million puts. Tesla (T...

Notable open interest changes for December 20th

Lazard Managed Equity Volatility Portfolio Q3 2024 Commentary

Tracking William Nygren's Harris Associates Portfolio - Q3 2024 Update

ACHC

ACLS

AGCO

ALGM

ALLY

AMKR

AMZN

APLS

ATKR

BIIB

BMRN

BMYMP

BRBR

CBRE

CHTR

CLVT

CMCSA

CNMD

CNXC

COLD

COLL

CRBG

CSCO

CTVA

DINO

DXCM

ENPH

FBIN

FCNCA

FIVN

FLNC

GEHC

GNTX

GOOG

GOOGL

HRMY

IART

ICUI

INTC

IONS

IPGP

KVUE

LNTH

MCHP

MRNA

MSTR

NDAQ

NEOG

NVDA

OPCH

PAYC

PTEN

QDEL

QRVO

REGN

REXR

RHHBF

RHHBY

RHHVF

RYAAY

SCHW

SEDG

SGRY

STNE

SWKS

SYNA

TSLA

VEEV

WOLF

XRAY

Press Releases

AcariaHealth Shines at the 2024 NASP Annual Meeting: Transforming Specialty Pharmacy

Contracts

CENTENE SUBSIDIARY BUCKEYE HEALTH PLAN AWARDED CONTRACT TO SERVE DUAL ELIGIBILE MEDICARE AND MEDICAID MEMBERS IN OHIO

Sunshine Health Announces the Appointment of Charlene Zein as President and CEO

Meridian Health Plan of Illinois and Liberty Bank and Trust Partner to Create Small Business Loan Program to Support and Empower Diverse and Small Businesses in Illinois

CENTENE CORPORATION TO HOST INVESTOR DAY ON DECEMBER 12, 2024

CENTENE FOUNDATION PARTNERS WITH THE NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS TO STRENGTHEN COMMUNITY HEALTH DELIVERY

CENTENE CORPORATION TO HOST VIRTUAL INVESTOR DAY ON DECEMBER 12, 2024

CENTENE CORPORATION ANNOUNCES 2025 GUIDANCE

Superior HealthPlan Commemorates 25-year Anniversary by Awarding $25,000 Grant to NAMI El Paso

Health Net Providing Special Assistance to Members Affected by Bird Flu Throughout California

Comments

Centene

뉴스

에 대한 최신 뉴스 Centene (NYSE:CNC) 주식

일요일, 10월 20, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌